CMS Bona Fide Marketing Rule: What the D.C. Circuit Teva Ruling Actually Revived

On August 18, 2026, the U.S. Court of Appeals for the District of Columbia Circuit issued its unanimous panel decision in Teva Pharmaceuticals USA, Inc. v. Kennedy (No. 25-5425), handing the pharmaceutical industry its first substantive appellate win in the multi-front legal campaign against the Medicare Drug Price Negotiation Program established under the Inflation Reduction Act of 2022 (IRA; P.L. 117-169).

Trade headlines immediately framed the ruling as "reviving Teva's IRA lawsuit." While technically accurate, that shorthand obscures what the court actually held—and what it deliberately left untouched.

The D.C. Circuit did not strike down the Medicare negotiation program, did not find CMS's negotiation rules unlawful, and did not shield Teva’s blockbuster movement-disorder brand Austedo (deutetrabenazine) from its scheduled January 1, 2027 Maximum Fair Price (MFP). Instead, the panel held that Teva’s facial statutory challenge to CMS’s bona fide marketing standard for generic-driven deselection is legally ripe for judicial review, reversing the U.S. District Court for the District of Columbia’s November 20, 2025 dismissal for lack of ripeness (Teva Pharms. USA, Inc. v. Becerra, 2025 WL 3240267).

The court remanded the case for the district court to determine, in the first instance, whether CMS's regulatory threshold for recognizing generic market entry exceeds the statutory authority granted by Congress under 42 U.S.C. § 1320f-1.

For market-access leads, brand lifecycle planners, and generic launch strategists, this ruling creates a critical legal precedent: while drug-specific selection and pricing determinations remain strictly insulated from judicial review under the IRA's statutory jurisdiction bar (42 U.S.C. § 1320f-7(2)), generally applicable administrative standards created by CMS guidance are subject to facial review in federal court.

---

What did the D.C. Circuit actually decide in Teva v. Kennedy?

The 43-page opinion authored by Circuit Judge J. Michelle Childs—joined by Circuit Judges Karen LeCraft Henderson and Florence Pan—resolved four distinct legal questions arising from CMS’s implementation of the Medicare Drug Price Negotiation Program:

                       ┌─────────────────────────────────────────────────────────────┐
                       │               TEVA v. KENNEDY (D.C. CIR. 2026)              │
                       └──────────────────────────────┬──────────────────────────────┘
                                                      │
         ┌────────────────────────────────────────────┼────────────────────────────────────────────┐
         │                                            │                                            │
         ▼                                            ▼                                            ▼
┌──────────────────┐                         ┌──────────────────┐                         ┌──────────────────┐
│   QSSD Grouping  │                         │    Due Process   │                         │  Bona Fide Mktg  │
│     UPHELD       │                         │    REJECTED      │                         │     REMANDED     │
└────────┬─────────┘                         └────────┬─────────┘                         └────────┬─────────┘
         │                                            │                                            │
         ▼                                            ▼                                            ▼
Austedo & Austedo XR                         No protected property                        District Court must
stay one selected drug;                      interest in Medicare                         decide if CMS test
MFP lands Jan 1, 2027                        reimbursement rates                          violates IRA statute

The D.C. Circuit’s holding on the statutory jurisdiction bar represents the most consequential administrative law ruling in the IRA litigation track. Under 42 U.S.C. § 1320f-7(2), Congress specified that there shall be "no administrative or judicial review" of CMS determinations regarding selected drug eligibility, selection, and price ceiling calculations.

The panel held that while § 1320f-7(2) strips courts of jurisdiction to hear disputes over whether Drug X should have been selected or whether Price Y was properly calculated, it does not bar challenges asserting that CMS promulgated a regulation or guidance standard that conflicts with the governing statute.

---

What is the bona fide marketing standard and where does CMS get it?

To understand why Teva sued CMS over bona fide marketing, one must look at the IRA's statutory deselection trigger and how CMS operationalized it in administrative guidance.

Under Section 1192(c) of the Social Security Act (42 U.S.C. § 1320f-1(c)), a selected drug is removed from the negotiation program—meaning its Maximum Fair Price no longer applies—beginning on the first day of the year that begins at least 9 months after CMS determines that a generic competitor (or biosimilar) is approved by the FDA and "marketed" under 42 U.S.C. § 1320f-1(e)(1)(A)(iii).

The statute itself uses the simple word "marketed." However, in its Revised Guidance for Initial Price Applicability Year (IPAY) 2026 (Section 30.1) and subsequent IPAY 2027 Guidance (Section 30.1), CMS established a far more rigorous requirement: generic entry must constitute "bona fide marketing."

                       ┌─────────────────────────────────────────────────────────────┐
                       │          STATUTORY REQUIREMENT: 42 U.S.C. § 1320f-1         │
                       │          Generic is approved by FDA and "marketed"          │
                       └──────────────────────────────┬──────────────────────────────┘
                                                      │
                                                      ▼ CMS Interpretation
                       ┌─────────────────────────────────────────────────────────────┐
                       │              CMS "BONA FIDE MARKETING" STANDARD             │
                       │           Totality-of-the-Circumstances Investigation       │
                       └──────────────┬───────────────────────────────┬──────────────┘
                                      │                               │
                                      ▼                               ▼
                       ┌──────────────────────────────┐┌──────────────────────────────┐
                       │       Quantitative Data      ││     Qualitative Factors      │
                       ├──────────────────────────────┤├──────────────────────────────┤
                       │ • Part D PDE Claims Data     ││ • Supply & Distribution Vol. │
                       │ • Average Mfr Price (AMP)    ││ • Commercial Availability    │
                       │ • Ongoing Market Volume      ││ • Restriction Agreements     │
                       └──────────────────────────────┘└──────────────────────────────┘

CMS defines bona fide marketing as a holistic, totality-of-the-circumstances inquiry rather than a bright-line test:

1. Prescription Drug Event (PDE) Data: CMS monitors Part D claims data to verify whether actual commercial prescriptions for the generic drug are being adjudicated and dispensed across retail and specialty networks.
2. Average Manufacturer Price (AMP) Data: CMS audits manufacturer-submitted AMP filings under Section 1927 of the Social Security Act to confirm that commercial sales are occurring at volume.
3. Availability and Distribution: CMS investigates whether the generic manufacturer has sufficient supply in commercial distribution channels to meet regular and consistent patient demand.
4. Contractual and Licensing Restrictions: CMS evaluates whether commercial arrangements, patent settlements, or supply-chain bottlenecks restrict the generic from competing in earnest.

Teva argued that CMS’s bona fide marketing standard unlawfully erects extra-statutory barriers. Under Teva’s reading of Hatch-Waxman and the IRA, once a generic receives final FDA approval and commercially ships units into interstate commerce, it is "marketed" as a matter of law.

By requiring an open-ended review of claims volume, market share, and distribution depth, Teva contended that CMS transformed a straightforward statutory status into a discretionary administrative gatekeeper that delays brand deselection and forces manufacturers to sell at MFP even after generic competition has commenced.

For a detailed analysis of how CMS monitors generic and biosimilar market entry in practice, see our explainer on how CMS determines bona fide marketing for IRA selected drugs.

---

Why did the D.C. Circuit hold the challenge ripe now?

The central procedural battle in Teva v. Kennedy was ripeness. The district court had dismissed Teva’s bona fide marketing challenge in November 2025, reasoning that because no generic competitor had yet launched against Austedo, and because Teva had not yet launched its own generics against other selected drugs, the dispute was purely hypothetical.

The D.C. Circuit forcefully rejected that reasoning under the two-prong Abbott Laboratories ripeness doctrine:

1. Fitness for Judicial Decision

The court held that Teva’s challenge presents a purely legal question: does CMS’s bona fide marketing standard exceed the agency’s statutory authority under the IRA? The court noted that resolving this question does not require awaiting a specific generic launch or reviewing a concrete administrative record of a particular deselection denial.

2. Hardship to the Parties

The panel found that Teva demonstrated substantial, immediate operational hardship. Teva occupies a dual commercial posture: it is simultaneously an innovator manufacturer facing negotiation on Austedo, and the largest generic manufacturer in the United States developing and launching generic equivalents of competitors' selected drugs.

The court highlighted sworn record evidence that Teva has developed generic versions of five innovator drugs selected for IPAY 2027:

1. Xtandi (enzalutamide): Astellas/Pfizer prostate cancer therapy.
2. Ofev (nintedanib): Boehringer Ingelheim idiopathic pulmonary fibrosis therapy.
3. Linzess (linaclotide): AbbVie/Ironwood gastrointestinal therapy.
4. Xifaxan (rifaximin): Salix/Bausch Health IBS-D/hepatic encephalopathy therapy.
5. Otezla (apremilast): Amgen plaque psoriasis and psoriatic arthritis therapy.

The court noted that Teva’s declarant testified under oath that FDA had already approved Teva's generic Xtandi capsules, with launch planned shortly before August 13, 2027, and that no meaningful patent or exclusivity barrier blocked Teva's Ofev generic entry following the expiration of Boehringer's orphan exclusivity.

Because generic launch sequencing, manufacturing scale-up, and commercial contracting require years of capital allocation, the court held that Teva cannot be forced to launch "in the dark" without knowing whether its commercial shipments will trigger statutory deselection of the reference product or be trapped in CMS's bona fide marketing review.

---

The Orange Book reality: Teva's generic positions against IPAY-2027 drugs

To evaluate the operational stakes of the remand, we audited the FDA Orange Book relational dataset (snapshot 2026-07-25) across all five IPAY-2027 reference listed drugs (RLDs) targeted by Teva and its Actavis subsidiary:

                       ┌─────────────────────────────────────────────────────────────┐
                       │           TEVA'S IPAY-2027 GENERIC PIPELINE STAKES          │
                       └──────────────────────────────┬──────────────────────────────┘
                                                      │
         ┌──────────────────┬─────────────────────────┼─────────────────────────┬──────────────────┐
         │                  │                         │                         │                  │
         ▼                  ▼                         ▼                         ▼                  ▼
┌──────────────────┐┌──────────────────┐   ┌──────────────────┐   ┌──────────────────┐┌──────────────────┐
│     Xifaxan      ││      Xtandi      │   │      Otezla      │   │       Ofev       ││     Linzess      │
│   ANDA 208959    ││   ANDA 209614    │   │   ANDA 211897    │   │ ANDA (July 2024) ││ Pipeline ANDA    │
│  AB-Rated Final  ││ Approved (Blank) │   │ Approved (Blank) │   │ Exclusivity 2026 ││ Patent Gated     │
└──────────────────┘└──────────────────┘   └──────────────────┘   └──────────────────┘└──────────────────┘

The Orange Book records demonstrate why the ripeness holding is grounded in commercial reality:

1. Xifaxan (rifaximin): Actavis Laboratories FL holds ANDA 208959 with full therapeutic equivalence (AB rating) approved on March 19, 2026. This represents an immediate, market-ready generic presentation.
2. Xtandi (enzalutamide): Actavis holds ANDA 209614, approved in May 2021 with a blank TE code (indicating approved but unmarketed status pending settlement license dates). The court record confirmed an expected launch window approaching August 2027. For broader market context on enzalutamide ANDAs, see our analysis of Xtandi generic enzalutamide ANDA approvals.
3. Otezla (apremilast): Teva holds ANDA 211897, approved in August 2022 with a blank TE code, awaiting contractual launch clearance under Hatch-Waxman settlement terms.
4. Ofev (nintedanib): Teva filed its ANDA on July 30, 2024, and no approved Teva/Actavis nintedanib row appears in the Orange Book snapshot. Boehringer’s orphan exclusivity on the reference product expires September 6, 2026, after which the court's finding of "no meaningful barrier" points to a cleared regulatory path; first-wave nintedanib ANDAs from other sponsors were already approved in April 2026. For background on the nintedanib exclusivity stack, see our review of Ofev nintedanib generic entry orphan exclusivity.

---

Commercial stakes: Austedo's revenue trajectory and the IPAY-2027 MFP

While Teva won a procedural remand on bona fide marketing, it suffered a complete defeat on its effort to remove Austedo XR from Medicare price negotiation.

Teva argued that because Austedo (deutetrabenazine tablets, NDA 208082) was approved in April 2017 while Austedo XR (extended-release tablets, NDA 216354) was approved in February 2023, Austedo XR had not been on the market for the statutory 7-year eligibility threshold required for small-molecule selection under 42 U.S.C. § 1320f-1(e)(1).

The D.C. Circuit affirmed CMS's statutory interpretation, holding that the IRA defines a "qualifying single-source drug" by reference to the active moiety and the NDA holder, rather than individual dosage forms or supplemental applications. Because both formulations share the same active chemical entity (deutetrabenazine) and are marketed by Teva, CMS possessed explicit statutory authority to aggregate their Medicare Part D expenditure data.

                       ┌─────────────────────────────────────────────────────────────┐
                       │          AUSTEDO FRANCHISE FINANCIAL & ACCESS PROFILE       │
                       └──────────────────────────────┬──────────────────────────────┘
                                                      │
         ┌────────────────────────────────────────────┴────────────────────────────────────────────┐
         │                                                                                         │
         ▼                                                                                         ▼
┌──────────────────────────────────────────────┐                          ┌──────────────────────────────────────────────┐
│           Commercial Revenue Growth          │                          │           IPAY 2027 Negotiated Price         │
├──────────────────────────────────────────────┤                          ├──────────────────────────────────────────────┤
│ • Q2 2026 US Net Revenue: $676 Million       │                          │ • 30-Day Supply MFP: $4,093                  │
│ • YoY Net Revenue Growth: +37%               │                          │ • CMS 2024 List Price Baseline: $6,623       │
│ • FY2026 Revenue Guidance: $2.45B - $2.60B   │                          │ • Discount From 2024 List: 38% (per CMS)    │
│ • Austedo XR Dose Expansions Approved 2024   │                          │ • Statutory Mandate: Must be covered on all  │
│ • (One-Pill Once-Daily Strengths)            │                          │   Part D formularies starting Jan 1, 2027    │
└──────────────────────────────────────────────┘                          └──────────────────────────────────────────────┘

The financial stakes for Austedo are immense:

• Revenue Momentum: According to Teva’s Q2 2026 earnings report (July 29, 2026), Austedo generated $676 million in U.S. net revenue in the second quarter alone—a 37% increase year-over-year—prompting Teva to raise full-year 2026 Austedo guidance to $2.45–$2.60 billion.
• Formulary Conversion: The once-daily Austedo XR formulation, approved February 17, 2023, received additional one-pill strengths (30–48 mg and 18 mg) in 2024 and anchors Teva's commercial lifecycle strategy for the franchise.
• Negotiated MFP Discount: On November 23, 2025, CMS announced the IPAY-2027 maximum fair prices, setting Austedo/Austedo XR at $4,093 per 30-day supply—a 38% discount from the 2024 list-price baseline of $6,623 per 30-day supply in the CMS fact sheet. A peer-reviewed comparative pricing analysis (PMC13119479) estimates the negotiated price at roughly 15% below Austedo's estimated pre-IRA net price ($4,812), reflecting rebates that already compressed the list price.
• The Formulary Mandate Paradox: While the 15% price cut reduces gross margins per prescription, IRA selection carries a statutory counter-benefit: under 42 U.S.C. § 1395w-104(b)(3)(I), every Medicare Part D plan sponsor is legally required to include selected drugs with an effective MFP on its formulary. Following commercial coverage restrictions imposed by several major PBMs in early 2026, the 2027 statutory coverage mandate guarantees Austedo universal Part D formulary access.

For an overview of the ongoing calendar across the next wave of selected drugs, see our guide to IRA third cycle 2028 selected drugs.

---

What happens next on remand, and what should launch teams watch?

The D.C. Circuit's remand returns the bona fide marketing dispute to the U.S. District Court for the District of Columbia. The litigation timeline and strategic implications for biopharma access teams break down into several distinct phases:

1. Merits Briefing in the District Court (Late 2026 – Mid 2027)

On remand, Judge Sparkle L. Sooknanan of the U.S. District Court for the District of Columbia must decide whether CMS’s totality-of-the-circumstances test violates the Administrative Procedure Act (APA) by conflicting with the plain language of 42 U.S.C. § 1320f-1.

Teva will argue that "marketed" means commercial shipping under FDA approval; the Department of Justice (representing CMS) will argue that Chevron-style (or post-Loper Bright) statutory construction gives CMS inherent authority to ensure that sham or token shipments do not defeat the statutory price reductions enacted by Congress.

2. No Immediate Injunction on January 1, 2027 MFPs

Because the D.C. Circuit affirmed QSSD grouping and did not reach the merits of bona fide marketing, there is zero legal basis for an injunction delaying Austedo's January 1, 2027 MFP. All 15 IPAY-2027 negotiated prices will take effect as scheduled.

3. Impact on Deselected Precedents

If the district court ultimately invalidates CMS's bona fide marketing standard, CMS would be forced to adopt a purely mechanical "approval + commercial launch" rule.

This could accelerate deselection for future IPAY cycles, preventing CMS from keeping selected innovator drugs in the program after first generic shipments begin. However, it would not alter the historical deselection of drugs like Entresto, Stelara, and Xarelto, whose generic competitors have already established massive commercial volume.

4. A Replicable Playbook for Future IRA Challenges

By ruling that § 1320f-7(2) does not bar facial challenges to CMS regulations and guidance, the D.C. Circuit provided a roadmap for future lawsuits. Manufacturers challenging CMS's upcoming rules on Part B negotiation, biosimilar delay special rules, or manufacturer agreement terms now have a recognized jurisdictional doorway in the D.C. Circuit.

For additional perspective on how the D.C. Circuit evaluates federal health agency guidance standards, review our analysis of the D.C. Circuit 340B rebate model ruling.

---

Frequently Asked Questions

Did the D.C. Circuit strike down the bona fide marketing standard?

No. The D.C. Circuit did not invalidate or strike down the bona fide marketing standard. It held that Teva's facial statutory challenge is ripe for adjudication and remanded the case to the U.S. District Court for the District of Columbia to determine whether the standard complies with the IRA statute.

Does this ruling delay Austedo's January 1, 2027 negotiated price?

No. The court affirmed CMS's decision to group Austedo and Austedo XR as a single qualifying single-source drug and rejected Teva's Fifth Amendment due process claims. Austedo's Maximum Fair Price ($4,093 per 30-day supply) will take effect on January 1, 2027 across all Medicare Part D plans as scheduled.

How does CMS decide whether a generic is bona fide marketed?

Under Section 30.1 of CMS's negotiation guidance, the agency conducts a holistic, totality-of-the-circumstances review. It analyzes Medicare Part D Prescription Drug Event (PDE) claims data, manufacturer Average Manufacturer Price (AMP) submissions, commercial distribution volume, and potential licensing or settlement restrictions to ensure generic entry is meaningful rather than token.

Does the court's jurisdiction-bar holding apply to future IRA lawsuits?

Yes. The D.C. Circuit established a binding circuit precedent that while the IRA's statutory review bar (42 U.S.C. § 1320f-7(2)) blocks judicial review of specific drug selections and price computations, it does not bar federal courts from hearing facial APA challenges to generally applicable legal rules and standards established in CMS guidance.

Could winning on remand benefit Teva's generic business while hurting its brand business?

Yes. If CMS's bona fide marketing standard is replaced with a simpler launch-based standard, Teva can more easily trigger statutory deselection for competitor innovator drugs (like Xtandi, Ofev, or Xifaxan) when launching its own generic ANDAs, eliminating the innovator's mandatory Part D formulary advantage.

---

Sources

• United States Court of Appeals for the District of Columbia Circuit. Teva Pharmaceuticals USA, Inc. v. Kennedy, No. 25-5425 (D.C. Cir. Aug. 18, 2026). Opinion by Judge J. Michelle Childs.
  https://media.cadc.uscourts.gov/opinions/docs/2026/08/25-5425-2188755.pdf
• Centers for Medicare & Medicaid Services (CMS). Medicare Drug Price Negotiation Program: Revised Guidance for Initial Price Applicability Year 2026 and Final Guidance for 2027 (Section 30.1: Monitoring of Selected Drugs and Deselection).
  https://www.cms.gov/files/document/medicare-drug-price-negotiation-program-revised-guidance-ipay-2026.pdf
• Centers for Medicare & Medicaid Services (CMS). Fact Sheet: Negotiated Prices for Initial Price Applicability Year 2027. Published November 23, 2025.
  https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf
• United States Code. Title 42, Section 1320f-1 (Selection of Negotiation-Eligible Drugs) and Section 1320f-7 (Limitation on Administrative and Judicial Review).
  https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section1320f-1
• Teva Pharmaceutical Industries Ltd. Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands. Corporate Press Release, July 29, 2026.
  https://www.tevapharm.com/news-and-media/latest-news/teva-delivers-strong-q2-results-and-raises-outlook-for-all-three-key-innovative-brands-reflecting-contin
• PubMed Central (PMC). Assessment of Initial Price Applicability Year 2027 Maximum Fair Prices with Most-Favored-Nation Reference Country Prices. PMC13119479, 2026.
  https://pmc.ncbi.nlm.nih.gov/articles/PMC13119479/
• U.S. Food and Drug Administration (FDA). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Relational snapshot 2026-07-25; records for deutetrabenazine NDA 208082/216354, rifaximin ANDA 208959, enzalutamide ANDA 209614, apremilast ANDA 211897).
  https://www.accessdata.fda.gov/scripts/cder/ob/
• Georgetown Law O'Neill Institute. PhRMA & Manufacturer IRA Litigation Tracker: Teva Pharmaceuticals USA, Inc. v. Kennedy (D.D.C. No. 1:25-cv-00113 / D.C. Cir. No. 25-5425).
  https://litigationtracker.law.georgetown.edu/litigation/teva-pharmaceuticals-usa-inc-et-al-v-becerra-et-al/
• Milliman Insight. Medicare Drug Price Negotiation: Navigating the Next Wave of Maximum Fair Prices and Part D Benefit Design Implications.
  https://www.milliman.com/en/insight/medicare-drug-negotiation-next-maximum-fair-prices